$RLFTY News

MindMaze Therapeutics: Consolidating a Global Approach to Reimbursement for Next-Generation Therapeutics

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

Relief Therapeutics Shareholders Approve Business Combination with NeuroX

Relief Therapeutics Announces Positive Results from Pivotal Bioequivalence Study of RLF-OD032

Relief Therapeutics Publishes 2025 Half-Year Report

Relief Therapeutics Advances Publication of 2025 Half-Year Report

Relief Therapeutics Announces Proposed Business Combination with NeuroX, Successor to MindMaze

Relief Therapeutics Receives FDA Response to QIDP Request for RLF-TD011

Relief Therapeutics Announces Results of Annual General Meeting

Relief Therapeutics Receives FDA Rare Pediatric Disease Designation for RLF-TD011

Relief Therapeutics Publishes 2025 Annual General Meeting Agenda

Relief Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Relief Therapeutics Announces Conclusion of Merger Discussions with Renexxion

Relief Therapeutics Announces European Patent Office Decision to Grant Patent for RLF-TD011

Relief Therapeutics Completes Strategic Transition with Sale of GOLIKE Rights ex-US

Relief Therapeutics Provides Update on Potential Transaction with Renexxion

Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial

Relief Therapeutics Announces Filing of Form 15F to Terminate SEC Reporting Obligations

Relief Therapeutics Announces Positive Final Results of RLF-TD011 Clinical Trial in Epidermolysis Bullosa

Relief Therapeutics Signs Non-Binding Letter of Intent with Renexxion for Reverse Merger